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SHORT COMMUNICATION
Novel AARS2 gene mutation producing
leukodystrophy: a case report
Laszlo Szpisjak1, Nora Zsindely2, Jozsef I Engelhardt1, Laszlo Vecsei1,3, Gabor G Kovacs4 and Peter Klivenyi1
AARS2 gene (NM_020745.3) mutations result in two different phenotypic diseases: infantile mitochondrial cardiomyopathy and
late-onset leukoencephalopathy. The patient’s ﬁrst symptoms appeared at the age of 18 years with behavioral changes and
psychiatric problems. Some years later, extrapyramidal symptoms, cognitive impairment, nystagmus, dysarthria and pyramidal
symptoms also developed. The brain magnetic resonance imaging (MRI) indicated extensive white matter abnormalities. The
diagnosis of AARS2 gene mutations causing leukodystrophy was conﬁrmed by genetic testing. Segregation analysis conﬁrmed the
compound heterozygous state of the patient. Histological examination of the biopsy did not prove speciﬁc pathological
alterations. The clinical phenotype of our patient was compared with seven previously described patients suffering from
leukoencephalopathy caused by AARS2 mutations. We have documented a new, nonsense AARS2 gene mutation (c.578T4G,
p.Leu193*) and a known missense mutation (c.595C4T, p.Arg199Cys) associated with leukoencephalopathy in a male patient.
Clinical features, imaging characteristics and genetic testing are presented, and histological data from an AARS2-related
leukodystrophy patient are described for the ﬁrst time.
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INTRODUCTION
Mitochondrial disorders are frequently caused by dysfunction of the
oxidative phosphorylation system that results in energy deﬁcit in the
cells. This group of diseases is genetically heterogeneous as some of
the mitochondrial proteins are encoded by the mitochondrial DNA,
whereas the rest of them are translated from messenger RNAs
transcribed from the nuclear genome. The mitochondrial DNA
contains 22 mitochondrial transfer RNA (tRNA) and 2 mitochondrial
ribosomal RNA encoding genes, in addition to 13 protein encoding
genes that are subunits in the mitochondrial respiratory chain. Several
proteins involved in mitochondrial translation, such as initiation,
elongation and termination factors, tRNA-modifying enzymes and the
mitochondrial aminoacyl-tRNA synthetases (ARS2) are encoded by
nuclear genes.1
Two groups of aminoacyl-tRNA synthetases can be distinguished
based on their mitochondrial or cytoplasmic localization. These
enzymes are encoded by distinct nuclear genes, with the exception
of GARS and KARS, because these genes encode the glycyl- and
lysyl-tRNA syntethases in both positions. Aminoacyl-tRNA synthetases
play a signiﬁcant role in the initiation of translation by charging tRNAs
with their appropriate amino acids. All of these proteins have a
catalytic and an anticodon binding domain (see later aminoacylation
domain), and some of them, including mitochondrial alanyl-tRNA
synthetase, also have an editing domain that can deacylate mischarged
amino acids.2,3
Mitochondrial alanyl-tRNA synthetase protein is encoded by the
nuclear gene AARS2. Mutations of this gene result in two different
phenotypic disorders that have been previously described. Certain
mutations particularly affect the heart, producing a fatal, early-onset
cardiomyopathy,4–7 whereas others are associated with onset leukoence-
phalopathy and ovarian failure in females without cardiac involvement.8,9
Euro et al.7 stated that the cause of the distinct phenotypes is related to
the activity of the aminoacylation, with cardiomyopathy resulting from a
serious reduction in aminoacylation activity, and leukodystrophy result-
ing from only moderate reduction in activity.
To date, only seven patients have been identiﬁed with
AARS2-associated leukoencephalopathy and only one of them is male.
Here we report a young Caucasian male patient with a
leukodystrophy phenotype and a novel AARS2 gene mutation.
CASE PRESENTATION
Patient history and clinical data
The patient is a 29-year-old male with an uneventful perinatal period.
His grandparents, parents and his younger brother did not report any
neurological or psychiatric problems. The parents noted that the
patient’s behavioral changes began at the age of 18 years. At that time
he exhibited an alteration of personality, mania and paranoid
delusions. Therefore, he was admitted to a psychiatric unit, where
he underwent antipsychotic treatment. Some years later, extra-
pyramidal symptoms appeared and they were attributed to the side
effects of the antipsychotic drugs. Otherwise, his somatic and
1Department of Neurology, University of Szeged, Szeged, Hungary; 2Department of Biochemistry and Molecular Biology, University of Szeged, Szeged, Hungary; 3MTA-SZTE
Neuroscience Research Group, Szeged, Hungary and 4Institute of Neurology, Medical University of Vienna, Vienna, Austria
Correspondence: Dr P Klivenyi, Department of Neurology, University of Szeged, Semmelweis str 6, Szeged 6726, Hungary.
E-mail: klivenyi.peter@med.u-szeged.hu
Received 7 July 2016; revised 12 September 2016; accepted 12 September 2016
Journal of Human Genetics (2016), 1–5
& 2016 The Japan Society of Human Genetics All rights reserved 1434-5161/16
www.nature.com/jhg
intellectual development was normal until age 24 years, when signs of
cognitive impairment became obvious. Before this deterioration, the
patient was an excellent student in secondary school and also in
college. There was a rapid and progressive cognitive decline, and
during the following 2 years he evolved acalculia, orientation problems
and dysgraphia. Besides these abnormalities, the neurological
examination revealed horizontal and vertical nystagmus, dysarthria,
dysphagia and extrapyramidal symptoms, including rigor, hypo- and
bradykinesia, pyramidal symptoms such as Babinski sign and
brisk tendon reﬂexes and frontal release signs, including glabellar,
palmomental and sucking reﬂex and palmar grasp. Ophthalmoscopy
and cardiological investigation did not reveal any pathological signs.
Figure 1 (a–f) Brain magnetic resonance imaging (MRI) of the patient, (g–i) AARS gene sequencing of the patient and his parents and (j) structure of the
AARS2 gene. (a, b) T1-weighted, sagittal scans show corpus callosum involvement mainly in the frontal part and extended white matter abnormalities in the
frontoparietal region with relative sparing of the central area. (c, d) T2-weighted, axial scans demonstrate pronounced leukoencephalopathy. The arrow proves
the lesion of pyramidal tract in level of internal capsule. (e, f) Fluid-attenuated inversion recovery (FLAIR)-weighted, axial scans: the arrows show the
frontopontine tract involvement in the level of internal capsule and the cerebral peduncle. AARS2 gene sequence of the patient (g) showing both mutations
(c.578T4G and c.595C4T). DNA sequence of the patient’s father (h) and mother (i) demonstrating only one mutation, conﬁrming the compound
heterozygosity of the subject. Genomic structure of AARS2 (j) with exons coding for the aminoacylation (green), editing (yellow) and C-terminal (black)
domains. The blue arrows (upper) indicate the position of mutations causing infantile mitochondrial hypertrophic cardiomyopathy. The lower arrows indicate
the position of mutations causing leukoencephalopathy. The mutations of our patient indicated red color, whereas the other mutations resulting in
leukodystrophy signed black color. The nonsense mutation (p.Leu193*) was reported here for the ﬁrst time, whereas the missense mutation (p.Arg199Cys)
has been described previously.5,6,8 A full color version of this ﬁgure is available at the Journal of Human Genetics journal online.
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The patient is still alive and is currently bedridden because of the
severe neurological deﬁcits.
MRI abnormalities
The brain magnetic resonance imaging (MRI) represented extensive
white matter abnormalities, predominantly present in the frontal
and parietal lobe, with a relative sparing of the central region.
The corpus callosum was affected as well, especially the frontal
part. Pyramidal tract involvement is represented at the level of
the internal capsule. In addition, the frontopontine ﬁbers are
speciﬁcally affected within the internal capsule and in the brainstem
(Figures 1a–f).
Figure 2 Representative histopathological images of the biopsy sample. (a) Hematoxylin and eosin (HE) staining of the cortex reveals preserved neurons.
HE (b), Klüver–Barrera (c), immunostaining for myelin basic protein (d), HLA-DR (microglia marker) (e) and SMI-31 (neuroﬁlament) (f) of the white matter
does not show disease-speciﬁc alterations, inﬂammation or demyelination. A full color version of this ﬁgure is available at the Journal of Human Genetics
journal online.
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Laboratory ﬁndings
Numerous examinations were performed to determine the precise
diagnosis of this early-adulthood-onset leukodystrophy. The
laboratory ﬁndings, including a complete blood count, creatine kinase
and serum lactate, were normal. The parameters of the cerebrospinal
ﬂuid, including leukocytes, protein content and IgG index, were
within the normal range, and isoelectric focusing did not display any
abnormalities. PCR tests of the herpes simplex virus types 1 and 2
from the cerebrospinal ﬂuid and the HIV-1 test from blood were
negative. The serum levels of very long chain fatty acids and phytanic
acid were not elevated. The arylsulfatase-A and galactocerebrosidase
activity from leukocytes showed intact function of these enzymes.
The blood mass spectrometry for amino acids, acylcarnitine and
succinylacetone did not point to metabolic deviations. Filipin staining
in cultured ﬁbroblasts did not conﬁrm the diagnosis of Niemann–Pick
disease type C.
Genetic tests
Genetic testing for the most common vanishing white matter disease
causing gene EIF2B5 was also negative. Earlier genetic examinations
did not verify CADASIL (Cerebral Autosomal-Dominant Arteriopathy
with Subcortical Infarcts and Leukoencephalopathy) disease. Based on
the phenotype and the characteristic MRI features, targeted gene
sequencing of AARS2 (NM_020745.3) was performed. The sequencing
identiﬁed three variations: c.578T4G, c.595C4T and c.2188G4A
(Figure 1g). The c.578T4G single-nucleotide polymorphism can be
considered a pathogenic variation as it causes a nonsense mutation
(p.Leu193*) in exon 3 and is likely to result in messenger RNA
degradation by nonsense-mediated decay. This mutation was not
described earlier and it could not be found in the ExAC database
(The Exac Database; http://exac.broadinstitute.org/gene/
ENSG00000124608). The c.595C4T variation causes a missense
mutation (p.Arg199Cys) in exon 4 of the gene and its presence was
also detected in four unrelated patients with similar clinical
presentation.8 The frequency of this allele is 14/72 800 in the European
population (The Exac Database; http://exac.broadinstitute.org/variant/
6-44278885-G-A). The c.2188G4A single-nucleotide polymorphism
also results in a missense mutation (p.Val730Met), but it is considered
a polymorphism based on its high allele frequency in control subjects
(∼4% in the European population; The Exac Database; http://exac.
broadinstitute.org/variant/6-44270870-C-T). Segregation analysis
indicated that the pathogenic mutations are not in the same allele of
the AARS2 gene, as the patient’s father carries only the c.578T4G
nonsense mutation, whereas his mother bears only the c.595C4T
mutation. Consequently, the patient has a compound heterozygous
mutation resulting in a late-onset leukodystrophy (Figures 1h and i).
Figure 1j shows the aminoacylation, the editing and the C-terminal
domains of the AARS2 gene with our patient’s and the earlier
described mutations.
Histology
Before the identiﬁcation of the genetic abnormality, a biopsy sampling
from the frontal lobe, including cortex and white matter, was
performed by another department. There was a lack of necrotic
damage, inﬂammatory inﬁltration, neuronal changes or vascular
lesions in the hematoxylin–eosin staining. In the Klüver–Barrera
myelin staining, together with the immunostaining for myelin basic
protein and neuroﬁlament, we did not observe selective demyelination
or axonal changes. Furthermore, there was a lack of amyloid precursor
protein immunoreactive axonal bulbs. Immunostaining for CD3
(T cells), CD8 (cytotoxic T cells) and CD20 (B cells) was completely
negative. There was an absence of macrophage activity (CD68) and
only very minor microglial reaction was noted (HLA-DR). Screening
for pathological protein inclusion using immunostaining for ubiquitin
and p62 did not reveal unequivocal pathological deposits (Figure 2).
In summary, this biopsy did not indicate pathological alterations, in
particular not selective demyelination or axonal/myelin pathology.
Ethics approval and consent to participate
This study was approved by the ethical committee of the Faculty of
Medicine, University of Szeged. Written informed consent was
obtained from the patient for publication of this case report for
educational purposes.
DISCUSSION
In this paper we describe a patient with an early-adulthood-onset
leukodystrophy caused by a compound heterozygous mutation of the
AARS2 gene. One of these pathogenic mutations (c.578T4G) has not
been previously published, whereas the other (c.595C4T) has been
detected in four unrelated patients with leukodystrophy.8 To date,
AARS2 mutations have been reported in 11 subjects who have infantile
mitochondrial hypertrophic cardiomyopathy with early fatal outcomes
and 7 patients with late-onset leukodystrophy.4–9 Our patient’s
phenotype is consistent with the predictions described by Euro et al.7
Table 1 Comparison of the clinical phenotypes of our patient with the earlier described seven patients suffering from AARS2 mutation causing
leukoencephalopathy
P1 P2 P3 P4 P5 P6 P7 Our patient
Age at ﬁrst neurological
symptom(s) (years)
3 7 33 24 40 22 30 18
First neurological
symptom(s)
Impaired
balance
Learning
difﬁculties
Depression,
cognitive
decline
Tremor of the hands,
cognitive decline,
behavioral changes
Depression,
cognitive
deterioration
Gait
problems
Cognitive decline,
behavioral
changes
Paranoid delusions,
personality changes
Cerebellar symptoms + + + + − + + +
Cognitive deterioration + + + + + − + +
Psychiatric symptoms + − + + + + + +
Pyramidal signs + + − + − + + +
Dystonia − + − + − − − −
Epilepsy − − + − − − − −
Ovarian failure + Male + + + + + Male
The symbol ‘+’ indicates present and the symbol ‘− ’ indicates not present.
P1–7 patients have been described earlier with AARS2 mutation causing leukodystrophy.
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in 2015 that one nonsense mutation together with the milder
p.Arg199Cys mutation cause the phenotype of leukodystrophy. Similar
to the previous observation, our patient did not have any cardiac
symptoms and his symptoms began after childhood and progressed
rapidly. Behavioral changes were observed ﬁrst and then neurological
symptoms appeared, including progressive cognitive decline, frontal
lobe dysfunction, cerebellar and extrapyramidal signs. The brain
MRI abnormalities supported these symptoms, with extensive white
matter lesions of frontal and parietal predominance, whereas corpus
callosum, brainstem, pyramidal tract and frontopontine ﬁber
involvement were observed. The clinical and radiological ﬁndings of
our patient are similar to the subjects whose AARS2 gene mutation
caused leukodystrophy (Table 1). As the biopsy sample included a
region that was not severely affected, histopathological analysis did not
reveal any disease-speciﬁc alteration.
In summary, ovarian failure and late-onset leukoencephalopathy
raise the suspicion of the diagnosis of AARS2-associated leuko-
dystrophy and vanishing white matter disease. The characteristic
MRI abnormalities, the described neurological symptoms and the
progressive course of the disease could help in differentiation. This
novel form of leukodystrophy is extremely rare, with our patient being
the eighth patient in the literature and only the second male patient. In
this report we have identiﬁed a new, not previously published disease-
causing mutation and the very ﬁrst histological data of this disease.
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